Zacks Research Forecasts Higher Earnings for Teladoc Health

Teladoc Health, Inc. (NYSE:TDOC) – Analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Teladoc Health in a research note issued on Wednesday, May 14th. Zacks Research analyst R. Department now anticipates that the health services provider will earn ($0.26) per share for the quarter, up from their previous estimate of ($0.28). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.16) per share. Zacks Research also issued estimates for Teladoc Health’s Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.29) EPS and FY2027 earnings at ($0.85) EPS.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The firm had revenue of $640.49 million during the quarter, compared to analysts’ expectations of $639.44 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%.

TDOC has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on shares of Teladoc Health from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Bank of America lowered their target price on shares of Teladoc Health from $9.50 to $8.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Jefferies Financial Group dropped their price target on Teladoc Health from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, April 21st. Piper Sandler cut their price target on Teladoc Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group lowered their price objective on Teladoc Health from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. Twelve research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.71.

Teladoc Health Stock Up 3.8%

NYSE:TDOC opened at $7.52 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The firm’s 50-day moving average price is $7.58 and its 200-day moving average price is $9.37. The company has a market capitalization of $1.32 billion, a PE ratio of -1.30 and a beta of 1.82. Teladoc Health has a 1-year low of $6.35 and a 1-year high of $15.21.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. Golden State Wealth Management LLC raised its stake in Teladoc Health by 102.6% during the 1st quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider’s stock valued at $27,000 after buying an additional 1,690 shares during the last quarter. National Bank of Canada FI boosted its stake in shares of Teladoc Health by 79.4% in the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider’s stock worth $28,000 after buying an additional 1,581 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of Teladoc Health in the fourth quarter worth $29,000. Lindbrook Capital LLC increased its position in Teladoc Health by 78.9% during the fourth quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider’s stock valued at $33,000 after acquiring an additional 1,612 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in Teladoc Health in the first quarter valued at about $37,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Insider Activity at Teladoc Health

In other news, insider Adam C. Vandervoort sold 11,011 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $8.42, for a total transaction of $92,712.62. Following the completion of the transaction, the insider now directly owns 64,308 shares of the company’s stock, valued at $541,473.36. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.58% of the stock is currently owned by insiders.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.